This article is more than 5 years old. Information may no longer be current.
Cardiology Today’s Intervention’s top news from TCT
Click Here to Manage Email Alerts
SAN DIEGO — Cardiology Today’s Intervention was on-site at TCT 2018 to report on the latest developments in interventional cardiology. Here are the most popular stories from the meeting. Our readers were interested in transcatheter mitral valve repair for functional mitral regurgitation, anticoagulation strategies in patients with stenting and atrial fibrillation, CABG vs. PCI in left main disease, transcatheter aortic valve replacement vs. surgery in high-risk patients and more.
COAPT: MitraClip reduces hospitalization, mortality in HF, mitral regurgitation
SAN DIEGO — Patients with HF with moderate to severe or severe functional mitral regurgitation who underwent transcatheter mitral valve repair reduced the risk for HF hospitalization and mortality compared with patients treated with medical therapy alone, according to 2-year data from the COAPT trial presented at TCT 2018.
Long-term oral anticoagulation alone not sufficient in AF, CAD after stenting
SAN DIEGO — Noninferiority was not established for oral anticoagulation alone vs. oral anticoagulation with antiplatelet therapy in patients with AF and stable CAD more than 1 year after stenting, according to data from the OAC-ALONE study presented at TCT 2018.
MAIN-COMPARE: Outcomes similar in CABG, PCI for left main CAD
SAN DIEGO — Patients with significant left main CAD who underwent PCI had similar rates of death and a composite outcome up to 10 years compared with those who underwent CABG, according to data from the MAIN-COMPARE registry presented at TCT 2018.
Survival, stroke rates similar in high-risk TAVR vs. surgery at 5 years
SAN DIEGO — Patients with severe symptomatic aortic stenosis and high operative mortality risk after TAVR had similar 5-year survival and stroke rates compared with those who underwent surgical AVR, according to data presented at TCT 2018.
PADN-5: Pulmonary artery denervation shows promise
SAN DIEGO — Pulmonary artery denervation showed improved outcomes in patients with combined pre- and postcapillary pulmonary hypertension, according to the randomized, sham-controlled PADN-5 trial.
ABSORB IV: BVS noninferior to metallic DES if implanted optimally
SAN DIEGO — A polymeric bioresorbable vascular scaffold when implanted properly in the optimal patient population was noninferior to a metallic drug-eluting stent regarding target lesion failure and angina at 30 days and 1 year, according to data presented at TCT 2018.
SOLVE-TAVI: Valves, anesthesia strategies confer similar outcomes in symptomatic aortic stenosis
SAN DIEGO — A self-expanding valve was equivalent to a balloon-expandable valve for 30-day outcomes in patients with symptomatic aortic stenosis who underwent transfemoral transcatheter aortic valve replacement, according to data from the SOLVE-TAVI trial presented at TCT 2018.
In addition, local and general anesthesia strategies during TAVR resulted in similar outcomes, according to the study.
IMPERIAL: DES with polymer coating offers superior patency in PAD
SAN DIEGO — Patients with peripheral artery disease who received a drug-eluting stent with a polymer coating and a lower drug dose density had better patency compared with a DES without a polymer coating and a higher drug dose density, according to 12-month results from the IMPERIAL trial presented at TCT 2018 and published in The Lancet.